A phase i trial of the safety and immunogenicity of RG1-VLP, a candidate broadly protective vaccine for the prevention of HPV-associated cancer

Ended Awarded Last action

Contract number
HHSN26100012
Awardee
Awarding agency
Obligated
$0

Award facts

Opportunity
Contract value
$0.00 Current and potential, with all options
Completion date 100% complete
  • Current, with exercised options
  • Potential, with all options
NAICS code
541712 Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
PSC
AN12 Health R&D Services; Health Care Services; Applied Research
Set-aside
No set-aside
Competition
Full and Open Competition · 5 offers Multiple Award, Fair Opportunity
Pricing
Cost No Fee
Place of performance
Madison, WI 53715, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Supplemental Agreement for work within scope P00002 -$95,414
Other Administrative Action 1 $0
Original award $95,414

Quick answers

Who was awarded contract HHSN26100012?

HHSN26100012 was awarded to University Of Wisconsin System by National Cancer Institute (National Institutes of Health) on September 15, 2017.

How much is contract HHSN26100012 worth?

The government has obligated $0 on HHSN26100012.

Is contract HHSN26100012 an order under another contract?

Yes. HHSN26100012 is a delivery order under HHSN261201200033I, an indefinite delivery contract, on Cancer Prevention Agent Development Program 2012-2017.

Was contract HHSN26100012 competed?

The extent of competition for HHSN26100012 was full and open competition. The government received 5 offers.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award